TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer.
Saved in:
| Title: | TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. |
|---|---|
| Authors: | Anandhan S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Herbrich S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Goswami S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guan B; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen Y; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Macaluso MD; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jindal S; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Natarajan SM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andrewes SW; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiong L; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nagarajan A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Basu S; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tang DN; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Min J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maitra A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PadSharma@mdanderson.org.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PadSharma@mdanderson.org.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PadSharma@mdanderson.org.; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PadSharma@mdanderson.org. |
| Source: | Nature communications [Nat Commun] 2024 Jul 10; Vol. 15 (1), pp. 5291. Date of Electronic Publication: 2024 Jul 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-49189-x |
